​

LENZ Therapeutics Stock (NASDAQ:LENZ)

ForecastRevenueOwnershipFinancialsChartTranscripts
LENZ Therapeutics by TradingView

Previous Close

$24.50

52W Range

$15.70 - $50.40

50D Avg

$31.92

200D Avg

$31.22

Market Cap

$506.30M

Avg Vol (3M)

$1.01M

Beta

0.45

Div Yield

$7.21

LENZ Company Profile

LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

6

IPO Date

Mar 22, 2024

Website

LENZ Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/ServiceSep 25Jun 25
License$5.00M-
Reportable Segment-$5.00M

Fiscal year ends in Dec 23 | Currency in USD

LENZ Financial Summary

Dec 23Dec 22Dec 21
Revenue-$15.00M-
Operating Income$-73.11M$-105.64M$-60.44M
Net Income$-124.65M$-101.05M$-70.76M
EBITDA$-70.70M$-97.29M$-59.71M
Basic EPS$-15.30$-12.89$-8.54
Diluted EPS$-15.30$-12.89$-8.54

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts

Q3 25Nov 05, 25 | 8:30 AM
Q1 25May 09, 25 | 4:30 PM
Q4 24Mar 19, 25 | 4:30 PM

Peer Comparison

TickerCompany
NBTXNanobiotix S.A.
SPRYARS Pharmaceuticals, Inc.
ABUSArbutus Biopharma Corporation
RZLTRezolute, Inc.
GHRSGH Research PLC
TYRATyra Biosciences, Inc.
PRMEPrime Medicine, Inc.
MRVIMaravai LifeSciences Holdings, Inc.
SVRASavara Inc.
GERNGeron Corporation